BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BI 3000202 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BI 3000202\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07409181-5598@assetmemo.bio
DTSTAMP:20261121T003114Z
DTSTART;VALUE=DATE:20290204
DTEND;VALUE=DATE:20290205
SUMMARY:BI 3000202: Phase 2 readout est. (NCT07409181)
DESCRIPTION:BI 3000202\, phase 2\, Systemic Lupus Erythematosus.\nStudy: A 
 Study to Test Whether Different Doses of BI 3000202 Help People With Syste
 mic Lupus Erythematosus (SLE)\nEstimated primary completion: 4 February 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/bi-3000202#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07409181
URL:https://assetmemo.bio/drug/bi-3000202#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06878365-5598@assetmemo.bio
DTSTAMP:20261121T003114Z
DTSTART;VALUE=DATE:20291210
DTEND;VALUE=DATE:20291211
SUMMARY:BI 3000202: Phase 1 readout est. (NCT06878365)
DESCRIPTION:BI 3000202\, phase 1.\nStudy: A Study to Test How Well BI 30002
 02 is Tolerated by People With Type 1 Interferonopathies\nEstimated primar
 y completion: 10 December 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/bi-3000202#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06878365
URL:https://assetmemo.bio/drug/bi-3000202#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
